COX-2 signaling and cancer: New players in old arena

Current Drug Targets

Volumn 15, Issue 3, 2014, Pages 347-359

  Misra, Shashank ^a   Sharma, Kulbhushan ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Cancer; COXIBs; Cyclooxygenase 2; EP receptors; mPGES 1; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CELECOXIB; CURCUMIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; GEFITINIB; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MESSENGER RNA; NAPROXEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROTEIN BCL 2; PROTEIN KINASE B; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; THROMBOXANE A2; VALDECOXIB;

CLINICAL TRIAL (TOPIC); DRUG TARGETING; ENZYME INHIBITION; GENE SILENCING; HUMAN; NEOPLASM; NONHUMAN; PROSTAGLANDIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84896712484     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140127102915     Document Type: Review

References (133)

1. Eisinger AL, Prescott SM, Jones DA, Stafforini DM. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat 2007; 82(1-4): 147-54.
2. Kundu N, Yang Q, Dorsey R, Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 2001; 93(5): 681-6.
3. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
4. Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011; 30(3-4): 449-63.
5. Woodgett JR. Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin Cancer Biol 1994; 5(4): 269-75.
6. Rundhaug JE, Simper MS, Surh I, Fischer SM. The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 2011; 30(3-4): 465-80.
7. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 2001; 3(5): 50-60.
8. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004; 5(9): 241.
9. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355(9204): 646-8.
10. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99(21): 13926-31.
11. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J Biol Chem 1991; 266(20): 12866-72.
12. Takahashi Y, Ueda N, Yoshimoto T, et al. Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun 1992; 182(2): 433-8.
13. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268(12): 9049-54.
14. Ramsay RG, Ciznadija D, Vanevski M, Mantamadiotis T. Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int J Immunopathol Pharmacol 2003; 16(2 Suppl): 59-67.
15. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. Faseb J 1991; 5(9): 2304-12.
16. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005; 310(5756): 1966-70.
17. Eckmann L, Stenson WF, Savidge TC, et al. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest 1997; 100(2): 296-309.
18. Wallace JL, Keenan CM, Gale D, Shoupe TS. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992; 102(1): 18-27.
19. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378(6555): 406-9.
20. Cao C, Matsumura K, Yamagata K, Watanabe Y. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever. Brain Res 1996; 733(2): 263-72.
21. Miettinen S, Fusco FR, Yrjanheikki J, et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94(12): 6500-5.
22. Wang D, Patel VV, Ricciotti E, et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA 2009; 106(18): 7548-52.
23. Ehrich E, Schnitzer T, Kivitz A, et al, MK-966, a highly selective cox-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 1997; 40.
24. Kawabata A. Prostaglandin E2 and pain--an update. Biol Pharm Bull 2011; 34(8): 1170-3.
25. Ohki S, Ogino N, Yamamoto S, Hayaishi O. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1979; 254(3): 829-36.
26. Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and-2. Prostaglandins Other Lipid Mediat 2002; 68-69: 115-28.
27. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010; 16(5): 1384-90.
28. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10(3): 181-93.
29. Chell S, Kaidi A, Williams AC, Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006; 1766(1): 104-19.
30. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58(17): 3761-4.
31. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58(19): 4245-9.
32. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275(15): 11397-403.
33. Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood) 2008; 233(11): 1433-40.
34. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003; 289(2): 265-74.
35. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60(17): 4705-8.
36. Kozaki K, Koshikawa K, Tatematsu Y, et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001; 20(31): 4228-34.
37. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87(5): 803-9.
38. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002; 99(19): 12483-8.
39. Mohammad MA, Zeeneldin AA, Abd Elmageed ZY, et al. Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue. Mol Cell Biochem 2012; 366(1-2): 269-75.
40. Ji B, Liu Y, Zhang P, Wang Y, Wang G. COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int J Med Sci 2012; 9(3): 237-42
41. Krawczyk-Rusiecka K, Wojciechowska-Durczynska K, Cyniak-Magierska A, Adamczewski Z, Galecka E, Lewinski A. COX-2 expression in papillary thyroid carcinoma (PTC) in cytological material obtained by fine needle aspiration biopsy (FNAB). Thyroid Res 2011; 4(1): 3.
42. Omi Y, Shibata N, Okamoto T, Obara T, Kobayashi M. Immunohistochemical demonstration of membrane-bound prostaglandin E2 synthase-1 in papillary thyroid carcinoma. Acta Histochem Cytochem 2009; 42(4): 105-9.
43. Kettunen HL, Kettunen AS, Rautonen NE. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 2003; 63(16): 5136-42.
44. Bren-Mattison Y, Meyer AM, Van Putten V, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 2008; 73(3): 709-17.
45. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164(1): 361-70.
46. Di JM, Zhou J, Zhou XL, et al. Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res 2009; 40(4): 268-75.
47. Miyashita M, Makino H, Katsuta M, et al. Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma. J Nippon Med Sch 2006; 73(6): 308-13.
48. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004; 151(4): 837-45.
49. Gu S, Qin J. [The expression and clinical significance of HIF-1alpha, COX-2 and E-cadherin in patients with lung adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2011; 14(3): 219-26.
50. Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Gkermpesi M, Sotiropoulou-Bonikou G, Papavassiliou AG. EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Cell Oncol 2007; 29(6): 477-82.
51. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res 2009; 50 Suppl: S29-34.
52. Elder DJ, Paraskeva C. Induced apoptosis in the prevention of colorectal cancer by non-steroidal anti-inflammatory drugs. Apoptosis 1999; 4(5): 365-72.
53. Tarnawski AS, Jones MK. Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med (Berl) 2003; 81(10): 627-36.
54. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 2001; 15(14): 2742-4.
55. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010: 215158.
56. Lanas A. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective nonsteroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Dig Liver Dis 2001; 33 Suppl 2: S29-34.
57. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAIDrelated gastrointestinal side effects. Scand J Gastroenterol Suppl 1989; 163: 3-8.
58. Arroyo V, Gines P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986; 81(2B): 104-22.
59. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355(9): 873-84.
60. Pruthi RS, Derksen JE, Moore D, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12(7 Pt 1): 2172-7.
61. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 2012; 92(8): 1115-28.
62. Gogas H, Polyzos A, Stavrinidis I, et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2006; 17(12): 1835-41.
63. O'Byrne KJ, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007; 25(22): 3266-73.
64. Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer-a phase I study. Radiat Oncol 2006; 1: 9
65. Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009; 325(1-2): 107-19.
66. Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NFkappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett 2009; 282(2): 167-76.
67. Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis 2009; 30(2): 300-7.
68. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem 2007; 282(24): 17340-50.
69. Liu B, Shi ZL, Feng J, Tao HM. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 2008; 32(5): 494-501.
70. Chen XJ, Xiao W, Qu X, Zhou SY. NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. Neoplasma 2008; 55(3): 200-4.
71. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 2003; 95(19): 1440-52.
72. Chan MW, Wong CY, Cheng AS, et al. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. Oncol Rep 2007; 1 8(6): 1557-62.
73. Zhong Y, Xia Z, Liu J, Lin Y, Zan H. The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells. Oncol Rep 2012; (4): 1003-10.
74. Strillacci A, Griffoni C, Sansone P, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009; 315(8): 1439-47.
75. Friedman JM, Liang G, Liu CC, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69(6): 2623-9.
76. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23(4): 457-62.
77. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-8, 2 p following 8.
78. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98(11): 736-47.
79. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-42.
80. Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie 2010; 92(6): 660-4.
81. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed colorectal adenomas and cancer. Clin Cancer Res 2001; 7(9): 3971-76.
82. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001; 7(9): 2669-74.
83. Murakami M, Naraba H, Tanioka T, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275(42): 32783-92.
84. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003; 278(21): 19396-405.
85. Hanaka H, Pawelzik SC, Johnsen JI, et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA 2009; 106(44): 18757-62.
86. Kamei D, Murakami M, Sasaki Y, et al. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J 2010; 425(2): 361-71.
87. Xu D, Rowland SE, Clark P, et al. MF63 [2-(6-chloro-1Hphenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008; 326(3): 754-63.
88. Jegerschold C, Pawelzik SC, Purhonen P, et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci USA 2008; 105(32): 11110-5.
89. He S, Wu Y, Yu D, Lai L. Microsomal prostaglandin E synthase-1 exhibits one-third-of-the-sites reactivity. Biochem J 2011; 440(1): 13-21.
90. He S, Lai L. Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors. J Chem Inf Model 2011; 51(12): 3254-61.
91. Waltenberger B, Wiechmann K, Bauer J, et al. Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E(2) synthase-1 (mPGES-1). J Med Chem 2011; 54(9): 3163-74.
92. Liedtke AJ, Keck PR, Lehmann F, Koeberle A, Werz O, Laufer SA. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J Med Chem 2009; 52(15): 4968-72.
93. Gosselin F, Lau S, Nadeau C, Trinh T, O'Shea PD, Davies IW. A practical synthesis of m-prostaglandin E synthase-1 inhibitor MK-7285. J Org Chem 2009; 74(20): 7790-7.
94. Chang HH, Meuillet EJ. Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 2011; (15): 1909-34.
95. Finetti F, Terzuoli E, Bocci E, et al. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS One 2012; 7(7): e40576.
96. Deckmann K, Rorsch F, Geisslinger G, Grosch S. Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NFkappaB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1. Cell Signal 2012; 24(2): 460-7.
97. Zhou J, Joplin DG, Cross JV, Templeton DJ. Sulforaphane inhibits prostaglandin E2 synthesis by suppressing microsomal prostaglandin E synthase 1. PLoS One 2012; 7(11): e49744.
98. Koeberle A, Bauer J, Verhoff M, Hoffmann M, Northoff H, Werz O. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res Commun 2009; 388(2): 350-4.
99. Beales IL, Ogunwobi OO. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer 2010; 126(9): 2247-55.
100. Degousee N, Fazel S, Angoulvant D, et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008; 117(13): 1701-10.
101. Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, FitzGerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 2006; 103(39): 14507-12.
102. Wu D, Mennerich D, Arndt K, et al. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat 2009; 90(1-2): 21-5.
103. Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E(2) and prostaglandin E(2) receptors. Carcinogenesis 2011; 32(1): 86-92.
104. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006; 66(19): 9665-72.
105. Baryawno N, Sveinbjornsson B, Eksborg S, et al. Tumor-growthpromoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 2008; 10(5): 661-74.
106. Clark P, Rowland SE, Denis D, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbe nzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 2008; 325(2): 425-34.
107. af Forselles KJ, Root J, Clarke T, et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP (2) receptor antagonist. Br J Pharmacol 2011; 164(7): 1847-56.
108. Chen Q, Muramoto K, Masaaki N, et al. A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol 2010; 160(2): 292-310.
109. Jiang J, Dingledine R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 2013; 344(2): 360-7.
110. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis, Cancer Res 2006;66: 2923-27.
111. Ma X, Holt D, Kundu N, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013; 2(1): e22647.
112. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68(19): 7750-9.
113. Skålhegg B, Taskén K, Specificity in the cAMP/PKA signaling pathway, Differential expression, regulation and subcellular localization of subunits of PKA. Frontiers in Bioscience 1997; pp. 331-42.
114. Caretta A, Mucignat-Caretta C, Protein kinase A in cancer, Cancers 2011; 3: 13-26.
115. Pan MR, Hou MF, Chang HC, Hung WC. Cyclooxygenase-2 upregulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 2008; 283(17): 11155-63.
116. Chang SH, Ai Y, Breyer RM, Lane TF, Hla T. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 2005; 65(11): 4496-9.
117. Chang SH, Liu CH, Wu MT, Hla T. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat 2005; 76(1-4): 48-58.
118. Donnini S, Finetti F, Solito R, et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. Faseb J 2007; 21(10): 2418-30.
119. Hawcroft G, Ko CW, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007; 26(21): 3006-19.
120. Brudvik KW, Paulsen JE, Aandahl EM, Roald B, Tasken K. Protein kinase A antagonist inhibits beta-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. Mol Cancer 2011; 10: 149.
121. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberineinduced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 2012; 83(3): 385-94.
122. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30(2): 193-204.
123. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9(6): 667-76.
124. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276(21): 18075-81.
125. Pozzi A, Yan X, Macias-Perez I, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 2004; 279(28): 29797-804.
126. Kang JH, Song KH, Jeong KC, et al. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 2011; 11: 334.
127. Wang J, Xiao X, Zhang Y, et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012; 53(1): 77-90.
128. Glynn SA, Prueitt RL, Ridnour LA, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ERnegative, HER2-positive breast cancer. BMC Cancer 2010; 10: 626.
129. Noordermeer J, Klingensmith J, Perrimon N, Nusse R. dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature 1994; 367(6458): 80-3.
130. Peifer M, Berg S, Reynolds AB. A repeating amino acid motif shared by proteins with diverse cellular roles. Cell 1994; 76(5): 789-91.
131. Luu HH, Zhang R, Haydon RC, et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004; 4(8): 653-71.
132. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310(5753): 1504-10.
133. Ho M Y, Liang S M, Hung S W, Liang C M MIG-7 Controls COX-2/PGE2-Mediated Lung Cancer Metastasis. Cancer Res 2013; 73: 439-49.